Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atopic Dermatitis: full-pipeline trial registry
55 of 151 indexed Atopic Dermatitis trials are currently recruiting.
Corpus placement: #76 of 28,707 conditions by registered trial count.
151 US clinical trials · 55 currently recruiting · #76 of 28,707 conditions by registered trial count
Atopic Dermatitis: 151 US clinical trials tracked, 55 recruiting.
Atopic Dermatitis is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 55 of them currently open to new participants. 47 are in Phase 3-4 (later-stage) and 66 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 10 of these trials.
Enrollment posture brief
Registry condition atopic-dermatitis
OPEN 55 | RECR 36% | LATE 47 | EARLY 66 | RANK #76 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Acquired Brain Injury (36% recruiting · 11 trials)
Atopic Dermatitis lists 55 open slots (36% of 151 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atopic Dermatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atopic Dermatitis recruits in line with its size-band peers.
55 of 151 indexed trials (36.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Atopic Dermatitis trials is spread across many organizations.
Pfizer accounts for 10 of 151 trials (6.6%). 80 distinct sponsors appear on at least one study for this condition label.
-
Typical Atopic Dermatitis enrolment sits around 137 participants.
Median target enrolment is 137 among the 151 trials that report a genuine target (sentinel values excluded). 65 of those (43%) plan for fewer than 100 participants.
-
Atopic Dermatitis research is mostly interventional.
122 interventional and 29 observational studies make up this index (80.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
151 total, page 2 of 4
Ethnic Differences in Mechanisms of Action of Dupilumab
University of Michigan
NCT05268107
Topical Treatment for Atopic Dermatitis
Wake Forest University Health Sciences
NCT06244212
Dupilumab De-escalation in Pediatric Atopic Dermatitis
Johns Hopkins University
NCT06116526
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07262983
Molecular Signatures of Cutaneous Dupilumab Response
University of California, San Francisco
NCT05858619
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Target PharmaSolutions
NCT03661866
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
Bausch Health Americas
NCT00568997
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Amgen
NCT05882877
Systems Biology of Early Atopy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04798079
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie
NCT03568318
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Regeneron Pharmaceuticals
NCT02612454
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
Northwestern University
NCT01782703
A Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics
NCT06395948
Seal, Stopping Eczema and Allergy Study
Kari Nadeau, MD, PhD
NCT03742414
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company
NCT05559359
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
Shaperon
NCT06024499
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Pfizer
NCT07216027
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
Amgen
NCT06224192
A Study of Barzolvolimab in Patients With Atopic Dermatitis
Celldex Therapeutics
NCT06727552
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Q32 Bio
NCT05509023
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
AbbVie
NCT06718101
Tralokinumab for Dupilumab Failures
Psoriasis Treatment Center of Central New Jersey
NCT06773455
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
Pfizer
NCT07190430
Bodewell Products for the Treatment of Atopic Dermatitis
University of Alabama at Birmingham
NCT05566262
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
Northwestern University
NCT03051347
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
AbbVie
NCT03569293
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Amgen
NCT05724199
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
NCT02260986
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Amgen
NCT05651711
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
AOBiome
NCT04490109
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Amgen
NCT05704738
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Eli Lilly and Company
NCT04178967
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
Eli Lilly and Company
NCT04146363
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Northwestern University
NCT00879944
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
Organon and
NCT05014568
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
Organon and
NCT05032859
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
NCT01859988
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
DS Biopharma
NCT02864498
Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).
LEO Pharma
NCT03526861
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
University of Southern California
NCT03981926
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company
NCT03443024
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
Chugai Pharmaceutical
NCT01986933
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Incyte Corporation
NCT06238817
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
LEO Pharma
NCT05958407
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
Eli Lilly and Company
NCT04250337
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Amgen
NCT05899816
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company
NCT04250350
Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
Nucryst Pharmaceuticals
NCT00076375
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
Vanda Pharmaceuticals
NCT02651714
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
PreCision Dermatology
NCT01826461
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 48 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Top Sponsors
Named interventions
Most-linked intervention names on Atopic Dermatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atopic Dermatitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atopic Dermatitis page
151 registered trials, 55 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 55 Atopic Dermatitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Atopic Dermatitis trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atopic Dermatitis condition card totals 151 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.